Exploration of Neuroprotective Therapy

Disease	Innate immunity	Adaptive immunity
AD	Chemokines, cytokines, and complements are all expressed in amyloid plaques. In vitro, Aβ induces innate immune expression. Aβ clearance is aided by microglia	As a therapeutic approach, activation of the adaptive immune system against Aβ peptide will aid clearance

Declarations

Acknowledgments

Thanks are due to CEHTI and the bioinformatics lab of the Department of Biotechnology and Bioinformatics, Jaypee University of Information technology, Solan, Himachal Pradesh, India for the technical help.

Author contributions

TRS: Conceptualization, Writing—review & editing. AS: Writing—original draft, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Gleerup HS, Hasselbalch SG, Simonsen AH. Biomarkers for Alzheimer’s disease in saliva: a systematic review. Dis Markers. 2019;2019:4761054. [DOI] [PubMed] [PMC]

Hardy J. A hundred years of Alzheimer’s disease research. Neuron. 2006;52:3–13. [DOI] [PubMed]

Rajan KB, Wilson RS, Weuve J, Barnes LL, Evans DA. Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. Neurology. 2015;85:898–904. [DOI] [PubMed] [PMC]

Alves L, Correia ASA, Miguel R, Alegria P, Bugalho P. Alzheimer’s disease: a clinical practice-oriented review. Front Neurol. 2012;3:63. [DOI] [PubMed] [PMC]

Alzheimer’s Association. 2019 Alzheimer’s disease facts and figures. Alzheimers Dement. 2019;15:321–87. [DOI]

Silva MVF, Loures CMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MDG. Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci. 2019;26:33. [DOI] [PubMed] [PMC]

Gunawardena IPC, Retinasamy T, Shaikh MF. Is Aducanumab for LMICs? Promises and challenges. Brain Sci. 2021;11:1547. [DOI] [PubMed] [PMC]

Shukla R, Singh TR. High-throughput screening of natural compounds and inhibition of a major therapeutic target HsGSK-3β for Alzheimer’s disease using computational approaches. J Genet Eng Biotechnol. 2021;19:61. [DOI] [PubMed] [PMC]

Kumar A, Singh TR. A new decision tree to solve the puzzle of Alzheimer’s disease pathogenesis through standard diagnosis scoring system. Interdiscip Sci. 2017;9:107–15. [DOI] [PubMed]

10.

Kumar A, Bansal A, Singh TR. ABCD: Alzheimer’s disease biomarkers comprehensive database. 3 Biotech. 2019;9:351. [DOI] [PubMed] [PMC]

11.

Alibhai JD, Diack AB, Manson JC. Unravelling the glial response in the pathogenesis of Alzheimer’s disease. FASEB J. 2018;32:5766–77. [DOI] [PubMed]

12.

Alibhai J, Blanco RA, Barria MA, Piccardo P, Caughey B, Perry VH, et al. Distribution of misfolded prion protein seeding activity alone does not predict regions of neurodegeneration. PLoS Biol. 2016;14:e1002579. [DOI] [PubMed] [PMC]

13.

Heneka MT, Rodríguez JJ, Verkhratsky A. Neuroglia in neurodegeneration. Brain Res Rev. 2010;63:189–211. [DOI] [PubMed]

14.

Zhao J, Su M, Lin Y, Liu H, He Z, Lai L. Administration of amyloid precursor protein gene deleted mouse ESC-derived thymic epithelial progenitors attenuates Alzheimer’s pathology. Front Immunol. 2020;11:1781. [DOI] [PubMed] [PMC]

15.

Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosc. 2007;10:1387–94. [DOI] [PubMed]

16.

McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson’s disease. J Neurosci. 2006;26:9365–75. [DOI] [PubMed] [PMC]

17.

Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677–86. [DOI] [PubMed]

18.

Hanisch UK. Microglia as a source and target of cytokines. Glia. 2002;40:140–55. [DOI] [PubMed]

19.

Innes S, Pariante CM, Borsini A. Microglial-driven changes in synaptic plasticity: a possible role in major depressive disorder. Psychoneuroendocrinology. 2019;102:236–47. [DOI] [PubMed]

20.

Heese K, Hock C, Otten U. Inflammatory signals induce neurotrophin expression in human microglial cells. J Neurochem. 1998;70:699–707. [DOI] [PubMed]

21.

Colton CA, Mott RT, Sharpe H, Xu Q, van Nostrand WE, Vitek MP. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation. 2006;3:27. [DOI] [PubMed] [PMC]

22.

Carson MJ, Bilousova TV, Puntambekar SS, Melchior B, Doose JM, Ethell IM. A rose by any other name? The potential consequences of microglial heterogeneity during CNS health and disease. Neurotherapeutics. 2007;4:571–9. [DOI] [PubMed] [PMC]

23.

Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11:373–84. [DOI] [PubMed]

24.

Buchanan MM, Hutchinson H, Watkins LR, Yin H. Toll-like receptor 4 in CNS pathologies. J Neurochem. 2010;114:13–27. [DOI] [PubMed] [PMC]

25.

Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev. 2005;204:27–42. [DOI] [PubMed]

26.

Koopman JJE, van Essen MF, Rennke HG, de Vries APJ, van Kooten C. Deposition of the membrane attack complex in healthy and diseased human kidneys. Front Immunol. 2021;11:599974. [DOI] [PubMed] [PMC]

27.

Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid β plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008;28:6333–41. [DOI] [PubMed] [PMC]

28.

Cardona AE, Poprp EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9:917–24. [DOI] [PubMed]

29.

Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009;187:761–72. [DOI] [PubMed] [PMC]

30.

Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE. Inflammation and adaptive immunity in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2:a009381. [DOI] [PubMed] [PMC]

31.

Bartos A, Fialová L, Sřvarcová J, Ripova D. Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament. J Neuroimmunol. 2012;252:100–5. [DOI] [PubMed]

32.

Saleh IA, Zesiewicz T, Xie Y, Sullivan KL, Miller AM, Kuzmin-Nichols N, et al. Evaluation of humoral immune response in adaptive immunity in ALS patients during disease progression. J Neuroimmunol. 2009;215:96–101. [DOI] [PubMed]

33.

Romero-Ramos M, von Euler Chelpin M, Sanchez-Guajardo V. Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance? Hum Vaccin Immunother. 2014;10:852–67. [DOI] [PubMed] [PMC]

34.

Rodrigues MCO, Sanberg PR, Cruz LE, Garbuzova-Davis S. The innate and adaptive immunological aspects in neurodegenerative diseases. J Neuroimmunol. 2014;269:1–8. [DOI] [PubMed]

35.

Reynolds AD, Stone DK, Mosley RL, Gendelman HE. Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4⁺CD25⁺ T cells. J Proteome Res. 2009;8:3497–511. [DOI] [PubMed] [PMC]

36.

Farfara D, Lifshitz V, Frenkel D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer’s disease. J Cell Mol Med. 2008;12:762–80. [DOI] [PubMed] [PMC]

37.

Kellner J, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M. Autoantibodies against β-amyloid are common in Alzheimer’s disease and help control plaque burden. Ann Neurol. 2009;65:24–31. [DOI] [PubMed]

38.

Husemann J, Loike JD, Anankov R, Febbraio M, Silverstein SC. Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia. 2002;40:195–205. [DOI] [PubMed]

39.

Bsibsi M, Persoon-Deen C, Verwer RWH, Meeuwsen S, Ravid R, van Noort JM. Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia. 2006;53:688–95. [DOI] [PubMed]

40.

McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging. 2001;22:799–809. [DOI] [PubMed]

41.

Gasque P, Dean YD, McGreal EP, Vanbeek J, Morgan BP. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology. 2000;49:171–86. [DOI] [PubMed]

42.

Shukla R, Munjal NS, Singh TR. Identification of novel small molecules against GSK3β for Alzheimer’s disease using chemoinformatics approach. J Mol Graph Model. 2019;91:91–104. [DOI] [PubMed]

43.

McGreal E, Gasque P. Structure-function studies of the receptors for complement C1q. Biochemic Soc Trans. 2002;30:1010–4. [DOI] [PubMed]

44.

Webster S, Rogers J. Relative efficacies of amyloid β peptide (Aβ) binding proteins in Aβ aggregation. J Neurosci Res. 1996;46:58–66. [DOI] [PubMed]

45.

Panayiotou E, Fella E, Papacharalambous R, Malas S, Kyriakides T. The role of complement in ATTR amyloidosis: a new therapeutic avenue? Orphanet J Rare Dis. 2015;10:P3. [DOI]

46.

Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol Immunol. 2007;44:999–1010. [DOI] [PubMed]

47.

McGeer PL, McGeer EG. Mechanisms of cell death in Alzheimer disease—immunopathology. J Neural Transm Suppl. 1998;54:159–66. [DOI] [PubMed]

48.

Webster SD, Galvan MD, Ferran E, Garzon-Rodriguez W, Glabe CG, Tenner AJ. Antibody-mediated phagocytosis of the amyloid β-peptide in microglia is differentially modulated by C1q. J Immunol. 2001;166:7496–503. [DOI] [PubMed]

49.

Wyss-Coray T, Yan F, Lin AHT, Lambris JD, Alexander JJ, Quigg RJ, et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer’s mice. Proc Natl Acad Sci U S A. 2002;99:10837–42. [DOI] [PubMed] [PMC]

50.

Xia MQ, Hyman BT. Chemokines/chemokine receptors in the central nervous system and Alzheimer’s disease. J Neurovirol. 1999;5:32–41. [DOI] [PubMed]

51.

Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer’s disease. Nat Immunol. 2015;16:229–36. [DOI] [PubMed]

52.

Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13:397–411. [DOI] [PubMed] [PMC]

53.

Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol. 2008;9:857–65. [DOI] [PubMed] [PMC]

54.

Yasuno F, Kosaka J, Ota M, Higuchi M, Ito H, Fujimura Y, et al. Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment–dementia converters measured by positron emission tomography with [¹¹C]DAA1106. Psychiatry Res. 2012;203:67–74. [DOI] [PubMed]

55.

Tong L, Prieto GA, Kramár EA, Smith ED, Cribbs DH, Lynch G, et al. Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1β via p38 mitogen-activated protein kinase. J Neurosci. 2012;32:17714–24. [DOI] [PubMed] [PMC]

56.

Youm YH, Grant RW, McCabe LR, Albarado DC, Nguyen KY, Ravussin A, et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab. 2013;18:519–32. [DOI] [PubMed] [PMC]

57.

Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674–8. [DOI] [PubMed] [PMC]

58.

Cameron B, Tse W, Lamb R, Li X, Lamb BT, Landreth GE. Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer’s disease. J Neurosci. 2012;32:15112–23. [DOI] [PubMed] [PMC]

59.

Amor S, Woodroofe MN. Innate and adaptive immune responses in neurodegeneration and repair. Immunology. 2014;141:287–91. [DOI] [PubMed] [PMC]

60.

Deane D, Wu Z, Zlokovic BV. RAGE (Yin) versus LRP (Yang) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood-brain barrier. Stroke. 2004;35:2628–31. [DOI] [PubMed]

61.

Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9:907–13. [DOI] [PubMed]

62.

Yang J, Aschner M. Developmental aspects of blood-brain barrier (BBB) and rat brain endothelial (RBE4) cells as in vitro model for studies on chlorpyrifos transport. Neurotoxicology. 2003;24:741–5. [DOI] [PubMed]

63.

Levy-Lahad E, Bird TD. Genetic factors in Alzheimer’s disease: a review of recent advances. Ann Neurol. 1996;40:829–40. [DOI] [PubMed]

64.

Hayashi H, Campenot RB, Vance DE, Vance JE. Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1. J Neurosci. 2007;27:1933–41. [DOI] [PubMed] [PMC]

65.

Han X. The role of apolipoprotein E in lipid metabolism in the central nervous system. Cell Mole Life Sci. 2004;61:1896–906. [DOI] [PubMed]

66.

Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-β peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2009;8:16–30. [DOI] [PubMed] [PMC]

67.

Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer’s amyloid-β_1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106:1489–99. [DOI] [PubMed] [PMC]

68.

Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimers disease. Curr Alzheimer Res. 2007;4:191–7. [DOI] [PubMed]

69.

Weller RO, Nicoll JAR. Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. Neurol Res. 2003;25:611–6. [DOI] [PubMed]

70.

Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, et al. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J Clin Invest. 2003;112:415–22. [DOI] [PubMed] [PMC]

71.

Chaouchi N, Wallon C, Taieb J, Auffredou MT, Tertian G, Lemoine FM, et al. Interferon-alpha-mediated prevention of in vitro apoptosis of chronic lymphocytic leukemia B cells: role of bcl-2 and c-myc. Clin Immunol Immunopathol. 1994;73:197–204. [DOI] [PubMed]

72.

Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer’s mice. Nat Neurosci. 2002;5:1288–93. [DOI] [PubMed]

73.

Magnus T, Chan A, Grauer O, Toyka KV, Gold R. Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation. J Immunol. 2001;167:5004–10. [DOI] [PubMed]

74.

Gasque P, Jones J, Singhrao SK, Morgan BP. Identification of an astrocyte cell population from human brain that expresses perforin, a cytotoxic protein implicated in immune defense. J Exp Med. 1998;187:451–60. [DOI] [PubMed] [PMC]

75.

Takada LT. Innate immunity and inflammation in Alzheimer’s disease pathogenesis. Arq Neuropsiquiatr. 2017;75:607–8. [DOI] [PubMed]

76.

Meda L, Cassatella MA, Szendrei GI, Otvos L Jr, Baron P, Villalba M, et al. Activation of microglial cells by β-amyloid protein and interferon-γ. Nature. 1995;374:647–50. [DOI] [PubMed]

77.

Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001;21:8370–7. [DOI] [PubMed] [PMC]

78.

McGeer EG, McGeer PL. The importance of inflammatory mechanisms in alzheimer disease. Exp Gerontol. 1998;33:371–8. [DOI] [PubMed]

79.

Brazil MI, Chung H, Maxfield FR. Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer’s disease amyloid fibrils by microglia. J Bio Chem. 2000;275:16941–7. [DOI] [PubMed]

80.

Town T, Nikolic V, Tan J. The microglial “activation” continuum: from innate to adaptive responses. J Neuroinflammation. 2005;2:24. [DOI] [PubMed] [PMC]

81.

Paresce DM, Chung H, Maxfield FR. Slow degradation of aggregates of the Alzheimer’s disease amyloid β-protein by microglial cells. J Bio Chem. 1997;272:29390–7. [DOI] [PubMed]

82.

Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer’s disease amyloid β-protein via a scavenger receptor. Neuron. 1996;17:553–65. [DOI] [PubMed]

83.

Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates west nile virus entry into the brain causing lethal encephalitis. Nat Med. 2004;10:1366–73. [DOI] [PubMed]

84.

Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, et al. Microglial activation resulting from CD40-CD40L interaction after β-amyloid stimulation. Science. 1999;286:2352–5. [DOI] [PubMed]

85.

Calingasan NY, Erdely HA, Altar CA. Identification of CD40 ligand in Alzheimer’s disease and in animal models of Alzheimer’s disease and brain injury. Neurobiol Aging. 2002;23:31–9. [DOI] [PubMed]

86.

Town T, Tan J, Mullan M. CD40 signaling and Alzheimer’s disease pathogenesis. Neurochem Int. 2001;39:371–80. [DOI] [PubMed]

87.

Townsend KP, Town T, Mori T, Lue LF, Shytle D, Sanberg PR, et al. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid β-peptide. Eur J Immunol. 2005;35:901–10. [DOI] [PubMed]

88.

Minghetti L, Ajmone-Cat MA, de Berardinis MA, de Simone R. Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation. Brain Res Brain Res Rev. 2005;48:251–6. [DOI] [PubMed]

89.

Austin SA, Combs CK. Mechanisms of microglial activation by amyloid precursor protein and its proteolytic fragments. In: Lane TE, Carson M, Bergmann C, Wyss-Coray T, editors. Central nervous system diseases and inflammation. Boston: Springer; 2008. pp. 13–32.

90.

Simpson JE, Ince PG, Shaw PJ, Heath PR, Raman R, Garwood CJ, et al. Microarray analysis of the astrocyte transcriptome in the aging brain: relationship to Alzheimer’s pathology and APOE genotype. Neurobiol Aging. 2011;32:1795–807. [DOI] [PubMed]

91.

Tan MG, Chua WT, Esiri MM, Smith AD, Vinters HV, Lai MK. Genome wide profiling of altered gene expression in the neocortex of Alzheimer’s disease. J Neurosci Res. 2010;88:1157–69. [DOI] [PubMed]

92.

Cooper-Knock J, Kirby J, Ferraiuolo L, Heath PR, Rattray M, Shaw PJ. Gene expression profiling in human neurodegenerative disease. Nat Rev Neurol. 2012;8:518–30. [DOI] [PubMed]

93.

Miller JA, Woltjer RL, Goodenbour JM, Horvath S, Geschwind DH. Genes and pathways underlying regional and cell type changes in Alzheimer’s disease. Genome Med. 2013;5:48. [DOI] [PubMed] [PMC]

94.

Orre M, Kamphuis W, Osborn LM, Melief J, Kooijman L, Huitinga I, et al. Acute isolation and transcriptome characterization of cortical astrocytes and microglia from young and aged mice. Neurobiol Aging. 2014;35:1–14. [DOI] [PubMed]

95.

Vincenti JE, Murphy L, Grabert K, McColl BW, Cancellotti E, Freeman TC, et al. Defining the microglia response during the time course of chronic neurodegeneration. J Virol. 2016;90:3003–17. [DOI] [PubMed] [PMC]

96.

Srinivasan K, Friedman BA, Larson JL, Lauffer BE, Goldstein LD, Appling LL, et al. Untangling the brain’s neuroinflammatory and neurodegenerative transcriptional responses. Nat Commun. 2016;7:11295. [DOI] [PubMed] [PMC]

97.

Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, et al. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer’s disease not evident in mouse models. Cell Rep. 2018;22:832–47. [DOI] [PubMed]

98.

Pennisi M, Crupi R, Di Paola R, Ontario ML, Bella R, Calabrese EJ, et al. Inflammasomes, hormesis, and antioxidants in neuroinflammation: role of NRLP3 in Alzheimer disease. J Neurosci Res. 2017;95:1360–72. [DOI] [PubMed]

99.

Schultz J, Schwarz A, Neidhold S, Burwinkel M, Riemer C, Simon D, et al. Role of interleukin-1 in prion disease-associated astrocyte activation. Am J Pathol. 2004;165:671–8. [DOI] [PubMed] [PMC]

100.

Hennessy E, Griffin ÉW, Cunningham C. Astrocytes are primed by chronic neurodegeneration to produce exaggerated chemokine and cell infiltration responses to acute stimulation with the cytokines IL-1β and TNF-α. J Neurosci. 2015;35:8411–22. [DOI] [PubMed] [PMC]

101.

Shukla R, Singh TR. Identification of small molecules against cyclin dependent kinase-5 using chemoinformatics approach for Alzheimer’s disease and other tauopathies. J Biomol Struct Dyn. 2022;40:2815–27. [DOI] [PubMed]

102.

Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–7. [DOI] [PubMed] [PMC]

103.

Shinozaki Y, Shibata K, Yoshida K, Shigetomi E, Gachet C, Ikenaka K, et al. Transformation of astrocytes to a neuroprotective phenotype by microglia via P2Y₁ receptor downregulation. Cell Rep. 2017;19:1151–64. [DOI] [PubMed]

104.

Li B, Xia M, Zorec R, Parpura V, Verkhratsky A. Astrocytes in heavy metal neurotoxicity and neurodegeneration. Brain Res. 2021;1752:147234. [DOI] [PubMed] [PMC]

105.

Sullivan B, Robison G, Osborn J, Kay M, Thompson P, Davis K, et al. On the nature of the Cu-rich aggregates in brain astrocytes. Redox Biol. 2017;11:231–9. [DOI] [PubMed] [PMC]

106.

Sofroniew MV. Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci. 2015;16:249–63. [DOI] [PubMed] [PMC]

107.

Gee JR, Keller JN. Astrocytes: regulation of brain homeostasis via apolipoprotein E. Int J Biochem Cell Biol. 2005;37:1145–50. [DOI] [PubMed]

108.

Rajasekhar K, Govindaraju T. Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer’s disease. RSC Adv. 2018;8:23780–804. [DOI] [PubMed] [PMC]

109.

Fettelschoss A, Zabel F, Bachmann MF. Vaccination against Alzheimer disease: an update on future strategies. Hum Vaccin Immunother. 2014;10:847–51. [DOI] [PubMed] [PMC]

110.

Ott PA. Immune-modified response criteria—an iterative learning process? Nat Rev Clinl Oncol. 2018;15:267–8. [DOI] [PubMed]

111.

Pimenova AA, Raj T, Goate AM. Untangling genetic risk for Alzheimer’s disease. Biol Psychiatry. 2018;83:300–10. [DOI] [PubMed] [PMC]

112.

Gjoneska E, Pfenning AR, Mathys H, Quon G, Kundaje A, Tsai LH, et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer’s disease. Nature. 2015;518:365–9. [DOI] [PubMed] [PMC]

113.

Rather MA, Khan A, Alshahrani S, Rashid H, Qadri M, Rashid S, et al. Inflammation and Alzheimer’s disease: mechanisms and therapeutic implications by natural products. Mediators Inflamm. 2021;2021:9982954. [DOI] [PubMed] [PMC]